CUREMARK

Founded in 2007, Curemark is a private, clinical-stage biopharmaceutical company developing novel therapies for the treatment of serious unmet needs in neuro-developmental and neurodegenerative disorders. Curemark has a robust pipeline including their lead drug candidate, CM-AT, the first and only disorder-modifying therapy for Autism... Curemark is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of neurological and other disorders.

Also known as: Curemark, LLC